Lyell Immunopharma (LYEL) Payables (2020 - 2026)

Lyell Immunopharma has disclosed Payables across 7 years of filings, most recently posting $5.5 million for Q1 2026.

• Payables for Q1 2026 came in at $5.5 million, up 46.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 46.67% YoY), and the FY2025 annual result was $2.9 million, down 46.09% from the prior year.
• Payables came in at $5.5 million for Q1 2026 at Lyell Immunopharma, up from $2.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.5 million in Q1 2022 to a low of $2.6 million in Q3 2025.
• The 5-year median for Payables is $4.4 million (2023), against an average of $4.5 million.
• Across the five-year window, Payables sank 46.09% in 2025 and jumped 46.67% in 2026, its largest moves.
• Lyell Immunopharma's Payables stood at $3.9 million in 2022, then grew by 22.98% to $4.8 million in 2023, then advanced by 11.4% to $5.4 million in 2024, then tumbled by 46.09% to $2.9 million in 2025, then soared by 89.01% to $5.5 million in 2026.
• The last three Payables figures came in at $5.5 million (Q1 2026), $2.9 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.